大黄[庶虫]虫丸治疗慢性乙型肝炎的系统评价  

Dahuang Zhechong Wan for chronic hepatitis B:a systematic review

作　　者：邓艳芳[1] 屈乐[1] 宋亚南[1] 蒋燕[1] 

机构地区：[1]北京中医药大学基础医学院,北京100029

出　　处：《北京中医药大学学报》2015年第6期420-425,共6页Journal of Beijing University of Traditional Chinese Medicine

基　　金：北京市朝阳区协同创新资助项目(No.XC1420)

摘　　要：目的评价大黄虫丸治疗慢性乙型肝炎患者(CHB)的有效性。方法检索并筛选国内外期刊公开发表的大黄虫丸治疗CHB的随机对照试验(RCT),采用Rev Man5.2软件对肝功能疗效、肝纤维化疗效等进行Meta分析。结果共纳入21篇RCT。大黄虫丸独立应用0篇,联合应用21篇,合计1 731例,其中实验组875例,对照组856例。Meta分析结果显示,大黄虫丸联合应用组患者治疗后临床总有效率、HBe Ag转阴率、HBV-DNA转阴率、谷草转氨酶(AST)、总胆红素(TBil)优于对照组,且差异有统计学意义。结论治疗CHB,联合大黄虫丸组优于未联合大黄虫丸组。但受研究文献的质量影响,此结论还需高质量的文献进一步验证。Objective To evaluate the effectiveness of Dahuang Zhechong Wan（ Rhubarb and Eupolyphaga Pill） for Chronic Hepatitis B. Methods Randomized controlled trials（ RCTs） of Dahuang Zhechong Wan for Chronic Hepatitis B published in domestic or foreign magazines were searched. Revman5. 2 was used to perform the Meta-analysis on the curative effect of Dahuang Zhechong Wan for chronic hepatitis B. Results A total of 21 RCTs were included,among which none used Dahuang Zhechong Wan only. 21 studies all used combined treatment on 1731 cases with 875 in treatment groups and 856 in control groups. The results of meta-analyses showed that at the end of the treatment,groups adding Dahuang Zhechong Wan was superior to those without. There were significant difference in both the clinical efficiency,HBV-DNA negative conversion,HBe Ag negative conversion,ALT and TBil recovery.Conclusion Combined therapy using Dahuang Zhechong Wan is superior to conventional medicine alone for chronic hepatitis B. However,because of low quality of the included studies,high-quality and largescale RCTs are needed to provide further evidence.

关 键 词：大黄[庶虫]丸 慢性乙型肝炎 随机对照试验 系统评价 

分 类 号：R256.4[医药卫生—中医内科学]